GSK recently announced results from a survey of rheumatologists, nephrologists and internal medicine specialists, which showed that the COVID-19 pandemic and other factors prevented some people living with systemic lupus erythematosus (SLE) from getting optimal care in the past two years, increasing their risk for organ damage. SLE is the most common form of lupus, impacting millions of people worldwide and costing billions of dollars to manage.
DocWire News spoke with Dr. Roger A. Levy, GSK Global Medical Expert, Immunology & Specialty Medicine, to hear about how survey results.